PHARMACOLOGY & THERAPEUTICS

Executive Editors
W. C. Bowman, A. M. Breckenridge, A. C. Sartorelli.

CHEMOTHERAPY

CLINICAL PHARMACOLOGY & THERAPEUTICS

TOXICOLOGY

METABOLIC INHIBITORS

GENERAL & SYSTEMATIC PHARMACOLOGY

Volume Contents, Author index
and Subject index to
Volume 15

PERGAMON PRESS OXFORD · NEW YORK

PHARMACOLOGY & THERAPEUTICS

Chemotherapy, Toxicology and Metabolic Inhibitors

Executive Editor: A. C. Sartorelli

Yale University School of Medicine, Department of Pharmacology, 333 Cedar Street, New Haven, Connecticut 06510, USA

Managing Editor: Barbara Z. Renkin, Ph.D.

General and Systematic Pharmacology

Executive Editor: W. C. Bowman

University of Strathclyde, Department of Physiology & Pharmacology, Royal College, 204 George Street, Glasgow G1 1XW, Scotland

Clinical Pharmacology and Therapeutics

Executive Editor: A. M. Breckenridge

University of Liverpool, Department of Pharmacology & Therapeutics, P.O. Box 147, Liverpool L69 3BX, England

Editorial Board

G. E. Adams—*Sutton, Surrey, England*
S. Agoston—*Groningen, Netherlands*
Joseph R. Bertino—*New Haven, Connecticut*
R. T. Brittain—*Ware, Hertfordshire*
Ernest Bueding—*Baltimore, Maryland*
B. A. Callingham—*Cambridge, England*
Donald S. Coffey—*Baltimore, Maryland*
William A. Creasey—*Philadelphia, Pennsylvania*
P. F. D'Arcy—*Belfast, N. Ireland*
M. A. Denborough—*Canberra, Australia*
Robert L. Dixon—*Research Triangle Park, North Carolina*
Jürgen Drews—*Wien, Austria*
W. F. Dryden—*Edmonton, Alberta, Canada*
B. L. Furman—*Glasgow, Scotland*
George A. Galegov—*Moscow, USSR*
C. F. George—*Southampton, England*
Evgeny Golovinsky—*Sofia, Bulgaria*
Robert E. Handschumacher—*New Haven, Connecticut*
Peter Langen—*Berlin, GDR*,
Åke Liljestrand—*Stockholm, Sweden*
Jerry Mitchell—*Houston, Texas*
A. Nies—*Denver, Colorado*
E. E. Ohnhaus—*Essen, German Federal Republic*
M. L'E. Orme—*Liverpool, England*
Robert E. Parks, Jr.—*Providence, Rhode Island*
Sidney Pestka—*Nutley, New Jersey*
William H. Prusoff—*New Haven, Connecticut*
J. L. Reid—*Glasgow, Scotland*
A. Richens—*London, England*
D. S. Savage—*Glasgow, Scotland*
D. G. Shand—*Durham, North Carolina*
David Shugar—*Warsaw, Poland*
F. Sjöqvist—*Huddinge, Sweden*
Jan Škoda—*Prague, Czechoslovakia*
A. Stafford—*Glasgow, Scotland*
Donald J. Tipper—*Worcester, Massachusetts*
E. S. Vesell—*Hershey, Pennsylvania*
George Weber—*Indianapolis, Indiana*
Gerhard Zbinden—*Zürich, Switzerland*

Library Annual Subscription Rates—published in 4 volumes per annum of 3 issues each. Annual Subscription, 1983, U.S. $800.00 including postage and insurance. 2 years, 1983/84, U.S. $1520.00. *Specially Reduced Rates to Individuals*: Any individual whose institution takes out a library subscription may purchase a second or additional subscription for personal use at a much reduced rate of $350.00 annually. Subscribers to the Journal may claim a 20% discount off Encyclopedia volumes.

Subscription enquiries from customers in North America should be sent to: Pergamon Press Inc., Maxwell House, Fairview Park, Elmsford, NY 10523, USA, and for the remainder of the world to: Pergamon Press Ltd, Headington Hill Hall, Oxford OX3, 0BW, England.

At the end of the year, the Subscriber will receive, free, both the annual subject index and an attractive and durable magazine binder, especially designed for *Pharmacology & Therapeutics*.

Copyright © 1982 Pergamon Press Ltd.

It is a condition of publication that manuscripts submitted to this journal have not been published and will not be simultaneously submitted or published elsewhere. By submitting a manuscript, the authors agree that the copyright for their article is transferred to the publisher if and when the article is accepted for publication. However, assignment of copyright is not required from authors who work for organisations which do not permit such assignment. The copyright covers the exclusive rights to reproduce and distribute the article, including reprints, photographic reproductions, microform or any other reproductions of similar nature and translations. No part of this publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means, electronic, electrostatic, magnetic tape, mechanical, photocopying, recording or otherwise, without permission in writing from the copyright holder.

U.S. COPYRIGHT LAW APPLICABLE TO USERS IN THE U.S.A.

The Article Fee Code on the first page of an article in this journal indicates the copyright owner's consent that in the U.S.A. copies may be made for personal or internal use provided the stated fee for copying beyond that permitted by Section 107 or 108 of the United States Copyright Law is paid. The appropriate remittance should be forwarded with a copy of the first page of the article to the Copyright Clearance Center, Inc., 21 Congress Street, Salem, MA 01970. If a code does not appear, copies of the article may be made without charge, provided permission is obtained from the publisher. The copyright owner's consent does not extend to copying for general distribution, for promotion, for creating new works or for resale. Specific written permission must be obtained from the publisher for such copying. In case of doubt please contact your nearest Pergamon office.

Microform Subscriptions and Back Issues

Back issues of all previously published volumes are available in the regular editions and on microfilm and microfiche. Current subscriptions are available on microfiche simultaneously with the paper edition and on microfilm on completion of the annual index at the end of the subscription year.

Publishing and Advertising Offices

Pergamon Press Ltd.
Headington Hill Hall
Oxford OX3 0BW
England

Pergamon Press Inc.
Maxwell House
Fairview Park, Elmsford
New York 10523, U.S.A.

Volume 15, 1982, Numbers 1–3

CONTENTS

Number 1 PAGE

The biological activity of the synthetic polyanion, pyran copolymer (Diveema, MVE, 46015) and the heterocyclic bis DEAE fluorenone derivative, tilorone and congeners: clinical and laboratory effects of these agents as modulators of host resistance: *W. Regelson* 1
Anti-rheumatic drugs: *T. R. Littler* 45
Drug interactions at excretory mechanisms: *L. Offerhaus* 69
Drug interactions occurring during absorption from the gastrointestinal tract: *J. P. Griffin* 79
The disulfiram and calcium carbimide acetaldehyde-mediated ethanol reactions: *J. E. Peachey and E. M. Sellers* 89
How to antagonize ethanol-induced inebriation: *M. Linnoila and M. J. Mattila* 99
The properties of brain nicotine receptors: *B. J. Morley* 111
Legionella toxin: *K. W. Hedlund* 123

Number 2

Quantitative structure–pharmacokinetic relationships and drug design: *J. K. Seydel and K.-J. Schaper* 131
Human smoking behavior and the development of dependence on tobacco smoking: *R. Stepney* 188
Smoking and drug metabolism: *G. W. Dawson and R. E. Vestal* 207
Pharmacological responses to the intracerebral administration of nicotine: *G. H. Hall* 223
The pharmacology of nicotine dependence: a working hypothesis: *D. J. K. Balfour* 239
Application of network thermodynamics to the computer modeling of the pharmacology of anticancer agents: A network model for methotrexate action as a comprehensive example: *J . C. White and D. C. Mikulecky* 251
The role of host hormones in controlling survival and development of *Schistosoma mansoni: P. M. Knopf* 293
Ultraviolet phototherapy of psoriasis: *J. A. Parrish* 313
Interactions of renal prostaglandins with the renin–angiotensin system: *P. C. Weber and W. Siess* 321

Number 3

Aeromonas toxins: Å. *Ljungh and T. Wadström* 339
Chimeric toxins: *S. Olsnes and A. Pihl* 355
Endotoxins of gram-negative bacteria: *O. Luderitz, C. Galanos and E. Th. Rietschel* 383
Shigella toxin(s): Description and role in diarrhea and dysentery: *G. T. Keusch, A. Donohue-Rolfe and M. Jacewicz* 403
Photobiologic principles of phototherapy and photochemotherapy of psoriasis: *J. A. Parrish* 439
Prostaglandins and regulation of blood pressure: clinical implications: *J. M. Sullivan* 447
The agonistic–antagonistic properties of clomiphene: a review: *J. H. Clark and B. M. Markaverich* 467
Drug metabolite kinetics: *J. B. Houston* 521
Antiarrhymic agents V – calcium blockers: *C. D. Burgess* 553

AUTHOR INDEX

Balfour, D. K. J. 239
Burgess, C. D. 553

Clark, J. H. 467

Dawson, G. W. 207
Donohue-Rolfe, A. 403

Galanos, C. 383
Griffin, J. P. 79

Hall, G. H. 223
Hedlund, K. W. 123
Houston, J. B. 521

Jacewicz, M. 403

Keusch, G. T. 403
Knopf, P. M. 293

Linnoila, M. 99
Littler, T. R. 45
Ljungh, A. 339
Luderitz, O. 383

Markaverich, B. M. 467
Mattila, M. J. 99
Mikulecky, D. C. 251
Morley, B. J. 111

Offerhaus, L. 69
Olsnes, S. 355

Parrish, J. A. 313, 439
Peachey, J. E. 89
Pihl, A. 355

Regelson, W. 1
Rietschel, E. Th. 383

Schaper, K. -J. 131
Sellers, E. M. 89
Seydel, J. K. 131
Siess, W. 321
Stepney, R. 188
Sullivan, J. M. 447

Vestal, R. E. 207

Wadström, T. 339
Weber, P. C. 321
White, J. C. 251

SUBJECT INDEX

Abrin
  antibody coupling 364
  properties and chimeric toxins 356–9
Absorption of drugs
  buccal and pH 148
  ionizable drugs 145–9
  and modification of drug structure 139–49
  quantitative structure–pharmacokinetic relationships 168–70
Acetaldehyde and alcohol sensitizing drugs 90
Acetazolamide and drug interactions at excretion 75
Acetohexamide, plasma concentration–time profile 536
Acetylaminosalicylic acid, plasma concentration–time profile 529, 530
Action potential, calcium effects 554, 555
Action spectrum of sunburn 441
Addiction *see* drug dependence, ethanol
Adverse drug reactions
  azathioprine 60
  calcium blockers 561, 562
  clomiphene 507–9
  corticosteroids 58
  cyclophosphamide 59
  gold 48, 49
  levamisole 63
  MVE 4, 6–8, 10, 15
  penicillamine 50–2
  tilorone 27
Aeromonas spp, biochemical characteristics 339, 341
Aeromonas hydrophila
  enzymes and toxins 340
  pathogenic role 346
Aeromonas toxins 339–51
  alpha-hemolysin 341–3
  beta-hemolysin 343–6
  enterotoxin effects 344–9
  fibroblast effects 342, 343
  rabbit intestinal loop effects 344, 350
  skulking mouse test 349
Alcohol sensitizing compounds 95
Alcohol sensitizing drugs 89–96 *see also* ethanol dose and ethanol dose 93, 94
Aldehyde-NAD oxidoreductase, drugs inhibiting 89
Aldosterone, prostaglandin interactions 331, 332
Alprenolol clearance and metabolism 548
Aminoacylxylidines, structure, lipophilicity and clearance 159
Aminophylline and ethanol effects 105
5-Aminosalicylic acid, plasma concentration–time profile 529
Amphetamine and ethanol effects 103
Amylobarbitone, serum concentration–time profile 546
Antibodies
  binding moiety and toxicity 372, 373
  lipopolysaccharides 390–3
  polyclonal 370
  toxic chimeras 361, 364, 370–5
Antidepressants, tricyclic, metabolism and smoking 214
Antipyrine
  metabolism and smoker age 212–14
  plasma concentration–time profile 547
Anti-tumor activity 31 *see also* MVE, tilorone
Antiviral acitvity 31 *see also* MVE, tilorone
Azathioprine in rheumatology 60

Barbiturates and drug absorption 81
Bayliss effect 447
Behavior
  discriminative and intracerebral nicotine 236, 237
  human smoking *see* smoking
Benoxaprofen in rheumatology 61, 62
Benzodiazepine metabolism and smoking 215, 216
Blood pressure
  peripheral vascular resistance 448
  regulation and prostaglandins 447–60
Blood vessels, prostaglandin synthesis and release 449–52
Body temperature and intracerebral nicotine 226–8

Caffeine metabolism and smoking 217
Calcium and action potential 555
Calcium blockers
  antiarrhythmic effects 553–62
  atrial fibrillation 559
  current use 556
  electrophysiology 555–7
  history 553, 554
  interactions with drugs 562
  local anesthetics 557
  pharmacokinetics 558, 559
  side effects 561, 562
  supraventricular tachycardia 559, 560
  ventricular arrhythmias 560, 561
  Wolff–Parkinson–White syndrome 560
Cancer treatment, chimeric toxins 377
Carbamazepine, plasma concentration–time profiles and metabolite 544
Carbamide–acetaldehyde reaction 91, 92
  clinical use 95
  complications 94, 95
  drug effects 94
  factors affecting 92–4
  pharmacodynamics 89–92
Carbon monoxide and tobacco smoke 210
Cardiovascular system, response to intracerebral nicotine 223–6
Catalepsy and intracerebral nicotine 234

Cells
adrenal Y1 and *Aeromonas* enterotoxin 348
chinese hamster ovary (CHO) and cholera toxin 430
fibroblasts and hemolysin effects 342, 343
HeLa and *Shigella* cytotoxin effects 422, 423, 426, 427
NK and pyran 14
pyran effects 14, 15
Chimeric toxins 355–78
A chain coupling 364–6
activity 376–9
alternative ligands 360, 361
antibody conjugates 361, 370–5
applications 377, 378
cancer treatment 377
comparisons 375, 376
construction 361–4
hormone conjugates 360, 361, 369, 370
immunogenicity 377
lectins 360
protein synthesis inhibition 356–60
structure and toxic activity 376–8
Chloroquine, indications and dose in rheumatic disease 54, 55
Chrysotherapy 47 *see also* gold
Cigarettes *see also* smoking
composition changes 185
low-tar 186, 187
Clomiphene
agonistic–antagonistic properties 467–509
analogues 471
behavior effects 483, 484
cell stimulation 469–73
effects on blood and organs 486, 487
effects on males 487–9
estrogenicity 482
female mouse urogenital effects 473
female rat urogenital effects 473
fertility effects 477–85
fetal development effects 506
hyperestrogenization 507
hypothalamo-pituitary effects 477–85
implantation and pregnancy 484, 485
male rat toxicology 503, 504
mammary effects 486
mechanism of action 481–3
nomenclature 467, 468
nuclear binding 491–8
ovary effects 485, 486
pregnancy rate 505, 506
primate urogenital effects 474–7
receptor interactions 489–98
side effects 507, 508
steroidogenesis and cholesterol 498, 499
structure 467, 468, 487
synthesis steps 469
teratology 501–3
tissue accumulation 490, 491
toxicology in animals 499–504
toxicology in humans 504–9
treatment in humans 505
uterine growth 470
Clozic in rheumatology 62
Computer modeling
network thermodynamics 251–91
SPICE2 listings for network modeling 289–91
Convulsions, effects of intracerebral nicotine 234
Corticosteroids
contraindications 57
drug interactions 58, 59
guidelines for use 56
indications 56, 57
in rheumatology 56–9
versatility of preparations 58
Corticosterone, nicotine use 242–5
Corticotrophin in rheumatology 59
Cyanide in tobacco smoke 211
Cyclophosphamide in rheumatology 59
Cytochalasin B and *Shigella* cytotoxin effects 423
Cytochrome P-450 monooxygenase and tilorone 17

Dapsone in rheumatology 64
Diarrhea, *Shigella* toxin role 403–33
Diazepam, plasma concentration–time profile and metabolite 544
Diltiazam formula and calcium blocking 556
Distribution of drugs *see also* volume of distribution
and structure–activity relationships 171, 172
Disulfiram–acetaldehyde reaction 91, 92
clinical use 95
complications 94, 95
drug effects 94
factors affecting 92–4
pharmacodynamics 89–92
Doxapram and ethanol effects 105
Drug dependence
conditioning theories 240, 241
molecular theories 239, 240
nicotine 241–5
Drugs *see also* alcohol sensitizing, metabolism and individual drugs
absorption and fat 82, 83
absorption and food 81, 82
acidic and excretion 70–2
action, steps and processes 132
antiarrhythmic *see* calcium blockers
anticancer, network thermodynamics 251–91
antimalarial 54, 55
antirheumatic 45–65
basic and excretion 72–5
elimination 157–60
excretion interactions 69–77
gastrointestinal metabolism 83–5
immunosuppressive in rheumatology 59, 60
ion exchange properties 80
ionizable 145–9
interaction and gastrointestinal absorption 79–87
interaction mechanisms at excretion 74, 75
lipophilicity 142
metabolism 155–5
NSAID 61, 62
partition coefficient 140–7
protein binding 149–54
single dose, metabolite kinetics 525–39
structure–pharmacodynamic relationships 131–75
volume of distribution 154, 155
Dysentery
initiation 432
Shigella sp toxin role 403–33

Electromagnetic radiation 440–2
biological interactions 442
skin penetration 444
Elimination of drugs and structure–activity relationship 172, 173

Enclomiphene
and estrogen receptor 492
uterine effects 471
and vaginal opening 503
Endocytosis mechanisms 423
Endotoxins *see also* lipopolysaccharides
Gram-negative bacteria 383–97
lipid A 393–5
Enterotoxin *see Shigella* sp
Epidermal growth factor–ricin A chain toxic 369
Estrogen
model of action 490
Estrogen binding sites
rat uterus 493–5
uterine epithelium 494
uterine myometrium 495
uterine stroma 494
Ethacrynic acid and drug interactions in excretion 71, 74
Ethamoxytriphetol (MER-25), fertility effects 477–83
Ethanol
cellular effects 99, 100
elimination potentiation 101, 102
fatalaties 99
and inebriation 101
metabolism and smoking 217
organ effects 100
pharmacodynamic antagonists 102, 103
pharmacokinetic antagonists 101, 102
pharmacokinetics 100, 101
vitamin effects 105–7
Ethanol-induced inebriation, antagonism 99–107
Excretion
drugs and interactions 69–77
proximal convoluted tubule and drugs 70

Fat and drug absorption and distribution 82, 83
Fenclofenac in rheumatology 61
Folate metabolism and methotrexate 261
Folinic acid and methotrexate toxicity 278–80
Free–Wilson analysis 133, 134
Frusemide and drug interactions in excretion 70, 71, 74

Gastrointestinal diseases and drug absorption 86, 87
Gastrointestinal system
absorption and drug interactions 79–87
ionic interactions 80, 81
metabolism and drug interactions 83–5
motility and pH 79, 80
shigellosis effects 431
Gelonin properties in toxic chimeras 372
Glutethimide
clearance and metabolism 548
ingestion and metabolism 549
metabolism and smoking 214
Gold
antirheumatic effects 45–50
contraindications 50
formulations 46
history of use 45, 46
prescribing 47
side effects 48, 49
toxicity 49

Hansch analysis, structure–pharmacokinetic relationship 134–9
Hemolysins *see Aeromonas* toxins
Hormones
effects of intracerebral nicotine 231–3
properties in toxic chimeras 362, 363, 369, 370
and *Schistosoma* sp survival and development 298–309
steroid, mechanisms of action 497
Host resistance modulation 1–33
4-Hydroxypropranolol, plasma concentration–time profile 531
Hyperbaric oxygen and ethanol inebriation 102
Hypertension and kallikrein–kinin system 458–60
Hypertension, essential
prostaglandin and renin role 332–4

Immune response, tilorone effects 24–7
Interferon induction 1, 31

Kallikrein–kinin system
in hypertension 458–60
and prostaglandins 457, 458
Kidney, prostaglandin effects 453–5
Kirchhoff's laws 254, 255

Lectins, properties in toxic chimeras 362, 363, 367
Legionella spp toxins 123–9
immunization effects and source 129
in vitro studies 126
macrophage survival 127
new pneumonia agents 123
and PMN chemiluminescence 128
potential candidates 124–9
species designation 125
Legionella pneumophila, anion exchange separation 128
Legionnaire's disease 123, 124
Levamisole
in rheumatology 63, 64
toxicity 63, 64
Lidoflazine formula and calcium blocking 556
Lignocaine administration, metabolism and curve dose 532
Lipid A
biological activities 393
endotoxic principle 393–5
precursor molecule 390
structure 388, 389
substitutents and bacteria 390
Lipopolysaccharides 383–7 *see also* Lipid A
core 387, 388
effects of *Salmonella* sp in man 386
fate in experimental animals 395, 396
immunodeterminants 390–3
lipid A 388–90
mode of action in animals 395, 396
O-specific chains 387
Salmonella Ra 386
salt forms and activity 394
structure 387
Lithium and drug interaction in excretion 73, 75

Malabsorption, drug-induced 85, 86
Meperidine metabolism and smoking 217
Metabolism of drugs
  smoking effects 211–18
  structure–pharmacokinetic relationship 172–5
Metabolites, kinetics of drug 521–51
  applications 545–50
  availability 537, 538
  chronic administration 539–44
  clearance 538, 539
  covalent binding kinetics 549, 550
  disposition parameters 533–9
  drug fraction converted 538
  elimination characterization 545–7
  elimination rate constant 524, 534–6
  elimination rate limitation 524, 536
  extravascular 529–32
  formation rate constant 539
  formation rate limitation 535, 536
  infusion and plasma concentration 542, 543
  intravenous, elimination 526–8
  kinetic parameters and administration 534
  plasma concentration–time profiles 525–39
  secondary 533
  steady state concentration prediction 541
  steady state plasma concentration 539–41
  time course 521
  time profiles 523
Metabolite–drug interaction 543, 544
  autoinduction 544
  end product inhibition 544
Methotrexate
  addition and removal from media 270, 271
  cell effects *in vivo* 274–8
  computer modeling of network thermodynamics 251–91
  folate competition 267–9
  folate displacement 266
  intact cell effects 269–72
  mechanism of action 260–82
  membrane transport 261–7
  pharmacology 260–82
  polyglutamates and thymidylate synthase inhibition 280–2
  resistance and tumour cell property 272–4
  rheumatology 60
  toxicity and folinic acid 278–80
  transient analysis 263
  unidirectional membrane fluxes 262
Modeccin properties and chimeric toxin 356–9
Model *see also* network
  catenary metabolite 529, 533
  compartmental and drug absorption 142–4
  endocytosis exit 428
  estrogen action 490
  linear free energy related 134–40
  metabolite kinetics 521–5
  nicotine dependence 245–7
  nonlinear 140
  parallel metabolite formation 533
  pharmacological, salicylate fate 546
Morphine analgesics, rational design 160
Muricide and intracerebral nicotine 235
MVE (NSC46015, diveema)
  activity 3–5
  adjuvant actions 13–15
  anticoagulant effects 9, 10
  anti-inflammatory 12, 13
  anti-tumour agent 13
  biological activity 1–16
  calcium and action 12
  chemistry 5
  clinical role 15, 16
  clinical study 6, 7
  cytoplasmic blebs 10, 11
  endothelial binding 9
  herpes infection 13
  host resistance modulation 1–33
  macrophage activation 13–15
  nuclear and cytoplasmic effects 10–12
  plutonium poisoning 16
  structure 2
  toxicity 4, 6–8, 10, 15

Naloxone and ethanol effects 104, 105
Naphthoxylacetic acid, plasma concentration–time profile 527
Network modeling
  capacitance 253
  chemical reactions 255–8
  diffusion 253
  flow, force and resistance 252, 253
  folate and methotrexate 261–7
  methotrexate effects on tumor cells 276
  multistep 258–60
Network thermodynamics
  anti-cancer drugs 251–9
  users guide, SPICE2 program 284–9
Neuropeptides and ethanol 103, 104
Neurotransmitter release and intracerebral nicotine 236
Nicotine
  addiction 192, 193
  basis of dependence 247, 248
  chronic use and stress 244
  corticosterone levels and stress 242–5
  dependence, hypothesis 239–49
  dependence model 245–7
  intracerebral, responses 223–37
  positive reinforcer 241
  role in smoking 190–2, 239, 247
  tobacco smoke 209, 210
  withdrawal effects 241–4
Nifedipine formula and calcium blocking 556
Nociception and intracerebral nicotine 234, 235

Ovulation and clomiphene 498, 499
Oxidative deamination, gastrointestinal and drugs 85

Paracetamol, blood concentration–time profile 527
Pattern recognition and drug action 138, 139
D-Penicillamine
  anti-rheumatic effects 50–4
  contraindication 54
  gold comparison 51
  indications 52
  response assessment 53
  side effects 50–2
  structure 50
Penicillin neurotoxicity 155
Pentazocine metabolism and smoking 214, 215
Perhexiline formula and calcium blocking 556
pH, urinary and drug interactions 76
Pharmacokinetic properties and structural modification 139–74

Phenacetin
blood concentration–time profile 527
metabolism and smoking 212
Phenobarbital, hepatic effects 208
Phenytoin metabolism and smoking 216
Photochemotherapy *see also* ultraviolet therapy
principles in psoriasis 439–46
Phototoxicity 313
Placebo effect and clomiphene induced ovulation 509
Platelets, prostaglandin effects 452, 453
Polyanion
adjuvants 1
synthetic, biological action 2–7
Polycyclic aromatic hydrocarbons
hepatic effects 208
in tobacco smoke 207–9
Polyethylene sulfonate 7
Pontiac factor *see* Legionnaire's disease
Prenylamine structure and calcium blocking 556
Primidone, plasma concentration–time profile 526
Probenecid and drug interactions in excretion 72, 74
Procainamide clearance and metabolism 548, 549
Propoxyphene metabolism and smoking 215
Propranolol
metabolism and smoking 217, 218
plasma concentration–time profile 527, 531
Prostaglandin
blood pressure regulation 447–60
blood vessel effects 449–52
circulation regulation 447–9
and kallikrein–kinin system 457, 458
platelet effects 452, 453
renal effects 453–5
and renin–angiotensin system 455–7
Prostaglandins, renal
aldosterone interaction 331, 332
formation inhibition 326, 327
postmortem renal accumulation 322
potassium chloride loading 331
renal formation and metabolism 321, 322
renin–angiotensin system 321–34
renin interaction 323–7
role in hypertension 332–4
sodium chloride loading 330
Protein binding of drugs 149–54
displacement 152
elimination and metabolism 150
quantitative effects 150, 151
structure–activity relationships 170
volume of distribution 150
Psoriasis
phototherapy 439–46
ultraviolet therapy 313–19
Pyran *see* MVE
Pyrithioxine and ethanol effects 106

Quinidine, cardiac glycoside interaction and excretion 72, 73, 75

Receptor
probability of drug reaching and properties 141
Shigella toxin 422
steroid and clomiphene 489–98
Receptors, adrenergic and renin secretion 327
Receptor, estrogen; nuclear accumulation and drugs 492
Receptors, nicotine
brain, properties 111–19
cholinergic 112–18
ligand distribution 117, 118
neurotoxin binding studies 112–14
noncholinergic studies 118, 119
physiology 114, 115
subcellular distribution 115
Reflexes, intracerebral nicotine 230, 231
Renin
baroception and release 328
furosemide and secretion 328, 329
in vitro release and prostaglandins 325, 326
prostaglandin interaction 323–7
release and exogenous prostaglandin 324
renal release 322, 323
role in hypertension 332–4
secretion receptors 327–31
synthesis and arachidonic acid 325
Renin–angiotensin system 453
components 322, 323
functions and ion balance 329, 330
juxtaglomerular apparatus 322, 323
and kallikrein–kinin system 458
prostaglandin effects 455–7
renal prostaglandins 321–34
Respiration and intracerebral nicotine 228, 229
Rheumatoid arthritis, drug use 45–65
Ricin
anti-cancer effect of chimeric toxin 374, 375
properties and chimeric toxins 356–9, 372, 374, 375
RMI 11,002DA tolerance and tumour activity 28, 29

Salmonella abortus equi lipopolysaccharide 394
Salmonella typhimurium lipopolysaccharide 385
Schistosoma mansoni
adult transfer to rats 297, 298
cell mediated immune response 306, 307
hormone production regulation 308
hormone replacement therapy 307, 308
host–parasite interactions 294
hosts, permissive and nonpermissive 294, 295
life cycle and blocking 296
maturation stages and hosts 306
rat infection with cerceriae 296, 297
survival and host hormones 298–309
T cell deficient rats 300
thyroid hormone interactions 305–8
thyroid hormone levels and mouse infection 301, 302
Shiga toxin 407, 408, 425 *see also Shigella* enterotoxin
electrophoreis 413
purification 428
secretory effect 429
Shigella spp, epidemiology of infections 403, 404
Shigella spp toxins 360
cell release 411
characterization 411
culture medium and conditions 410, 411
cytotoxin, cell effects and assay 420–5
and disease 431–3
enterotoxin 425–31
historical studies 404–9

iron dependence 409, 410
metabolic activity and HeLa cell effects 422, 423, 426, 427
molecular weights 415
neurotoxin, lethal doses 416–19
neurotoxin relevance 432
pH stability 412
physiological properties 416–31
purification 412–16
role in diarrhea and dysentery 403–33
strains producing 409
transglutaminase inhibitors 424
Skin
optical properties 442–4
u.v. response 445, 446
Sleep, effects on intracerebral nicotine 233
Smokers, low and middle tar types 187
Smoking
amounts 183, 184
biotransformation of drugs 209
cessation techniques 198–202
changes of habits 185, 186
composition of population 184, 185
development 187–90
development and personality 190
drug metabolism 207–18
and ethanol effects 102, 103
factors influencing 187–9
human behavior 183–202
learned behavior and reinforcement 196–8
nicotine addiction 192, 193
nicotine role 190, 191, 239, 247
psychological tool 193–6
stress attenuation 195
Spironolactone and drug interactions in excretion 71, 72, 74
Steroidogenesis and enterotoxins 345
Stress, role of nicotine dependence 243–5
Structure–activity relationships
absorption 168–72
analysis methods 133–9
chimeric toxins 376, 377
distributions 170–3
and drug design 131–82
examples of quantitative 170–5
limitations 174
rational design 160–74
Sugars, properties and toxic chimeras 367–9
Sulfapyridines
dissociation constant and protein binding 150–2
urine pH and renal clearance 167
Sulfasalazine, use in rheumatology 64, 65
Sulfation, gastrointestinal and drug interaction 84, 85
Sulfonamides
structure–pharmacokinetic relationship 134
urine, pH and half-like 158

Theophylline metabolism and smoking 211, 212
Thymidylate synthase inhibition and methotrexate polyglutamates 280–2
Thyroid activity and human schistosomiasis 302
Thyroid hormones 302–4
assays 304
metabolite potency 304
regulation by *Schistosoma* sp 308
Schistosoma mansoni effects 305–9
serum levels 304
Thyrotrophin releasing hormone (TRH) and ethanol narcosis 104
Thyroxine (T4) 302
Tilorone (bis DEAE fluorenone)
anti-tumor activity 22–4
anti-tumor effects, clinical studies 27–9
cell effects 20, 21
clinical uses 29, 30
cytotoxicity 20
derivatives 16, 30, 31
drug metabolizing enzymes 17
eye lesions 22
host resistance 21, 22
host resistance modulation 16–31
immune response 24–7
interferon induction 17, 20, 21
nucleic acid complexing 18
polymerase effects 18, 19
side effects 27
structure 2, 16
teratogenesis 21
toxicity 28
Tobacco *see also* smoking
history of use 183, 184
smoke constituents 207–11
Toxins *see also* individual toxins
chimeric 355–78
cholera 430
cholera, intestinal loop effects 344
diphtheria 356–8, 409
diphtheria in chimeric toxins 356, 357, 372, 373
Gram-negative endotoxins 383, 397
single chain proteins 359, 360
Trace elements in tobacco smoke 210
Tranquillizers, metabolism in smoking 216
Transplantation rejection and tilorone 25
Transport and structural modification of drugs 139–49
Triiodothyronine (T3) 302
activities 303
Triparanol 400
structure 487
Tumour, tilorone effects 22–4, 27–9

Ultraviolet
absorption spectrum of skin 443
skin response 445, 446
Ultraviolet phototherapy 313–19, 439–46
action spectrum 314–16, 441
adjuncts 316–18
biological effects 314
components 317
long term effects 318, 319
photosensitization 317

Vasopressin and ethanol effects 104
Veillonella sp, cell surface 384
Verapamil
calcium blocking activity 555
clinical antiarrhythmic effects 559–61
drug interactions 562
Vitamin depletion, drug-induced 85, 86

Vitamins and ethanol effects 105, 106
Volume of distribution 154, 155

Warfarin metabolism and smoking 216, 217
Water intake and intracerebral nicotine 235
Withdrawal effects of nicotine 241–4
Wolff–Parkinson–White syndrome 560

Zuclomiphene
  and estrogen receptor 492
  sexual receptivity 483, 484
  uterine effects 471, 472
  and vaginal opening 503